Name: endobronchial ultrasound-guided intratumoral injection of cisplatin for the treatment of isolated mediastinal recurrence of lung cancer
Uploaded: 2017-02-12T14:00:00.000+00:00
Duration: 4 min 4 s
Description: Watch this Scientific Journal Video about Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer at JoVE.com

The authors have no acknowledgements.

EBUS-안내 시스플라틴으로 치료 모든 환자에 대한 자료를 검토 하였다. 플로리다 대학의 제도적 검토위원회는이 연구 (# IRB201400823)를 승인했다. 모든 데이터는 전향 적으로 수집하여 후 향적으로 분석 하였다. 다음의 등록 기준을 사용합니다. 1. 환자 선택 <ol><li> 조직 검사에서 확인 된 비 - 소세포 폐암 (NSCLC) 또는 비소 세포 폐암 (SCLC)를 가지며, 조직 학적 확인 된 재발이 18에서 80 세 사이의 선택 환자. 6 개월 이상에 대한 폐문 및 종격동 구조 방사선의 적어도 50 GY을받은 환자를 등록. EBUS 및 원격 전이를 통해 액세스 할 수있는 폐문, 종격동 제한 재발 환자 및 주변 기관지 구조 (림프절, 결절 및 질량)를 포함한다. </li><li> 멀티 징계 흉부 종양학 종양 보드에 이러한 모든 환자를 제시하고의 진행에 합의를 얻기다른 국소 치료 옵션의 부족으로 인해 tratumoral 시스플라틴. EBUS-안내 ITC 진행하기로 한 결정은 기관 흉부 종양학 종양 보드의 공동 추천해야한다. </li></ol> 2. 기관지 초음파 (EBUS)는 시스플라틴 주입을 -guided <ol><li> ITC에 대한 폐문, 종격동 및 주변 기관지 구조의 유연한 지경에 초음파 프로브에 내장 할 수 있습니다 실시간 시각화가 볼록 프로브 EBUS를 사용합니다. </li><li> 환자는 절차 이전에 적어도 6 시간 동안 경구 음식과 액체 절제 있는지 확인합니다. </li><li> 이전에 공개 된 문헌 9, 10에 기초하여, 세션 당 40 밀리그램의 최대 투여 량으로 1 ㎎ / ㎖의 농도로 수성 시스플라틴 용액을 만든다. 사용 직전 0.9 % NaCl 용액에서 동결 건조 시스플라틴 분말을 녹인다. </li><li> 정맥 시작에서 덱사메타손 10 mg의 및 온단세트론 8 mg을 보내기절차의 닝은 메스꺼움을 방지합니다. </li><li> 정맥 미다 졸람과 펜타닐을 사용하여 수면 마취와 절차를 수행 (IV). 절차 이전에 4 % 리도카인 분무 5 ㎖의 형태로 국소 마취를 사용한다. </li><li> 미다 졸람의 2 밀리그램과 펜타닐 50 μg의의 IV 주입 함께 시작합니다. 환자마다 1-2 분을 재평가하고 달성 수면 마취를 유지하기 위해 추가 1 밀리그램 미다 졸람, 25 μg의 펜타닐 루스 줄 (최소한 눌려 의식을 환자에게 지속적이고 독립적 특허기도를 유지할 수 있도록 보호 반사 유지, 언어 적 명령 및 물리적 자극)에 응답 남아있다. 각각 펜타닐과 미다 졸람, 200 μg의 10 밀리그램의 최대 허용 용량을 초과하지 마십시오. </li><li> 상기 심장 박동을 모니터링 연속 3 리드 심전도, 연속 맥박 산소 측정기, 호흡 속도 측정을 포함, 표준 모니터링을 사용합니다. 지역 ANEST를 제공합니다hesia 필요에 따라 보조 O 2. </li><li> 기도의 성대를 통해 범위를 사전. 확인 대상 병변을 찾습니다. </li><li> EBUS 프로세서를 켜고 생리 식염수 1-2 mL로 사용하여 범위의 끝에서 풍선을 팽창. 기도 벽에서 범위를 Flex와 병변을 찾습니다. 병변의 위치는 CT / PET 결과에 달려 있지만, 일반적인 위치의 일부 중 subcarinal 영역 좌우 paratracheal 영역과 좌우의 폐문 영역을 포함한다. </li><li> 범위의 작업 채널을 통해 칼집에 수납 된 22 G EBUS 바늘을 배포하고 위치에 고정. 주 : 주사 부위에 대한 정확한 수술 좌표가 없지만, 일반적으로 처리 된 부위의 일부는 (내측 좌우 주 기관지의 교차점에서) 중 subcarinal 측 방향 우측 주 기관지의 오른쪽 paratracheal를 (포함 , 왼쪽 paratracheal) 오른쪽 상단 로브 구멍 위에서 (, (오른쪽 상단 로브 구멍 아래 측면 근위 기관지의 intermedius는에서) 오른쪽 폐문 및 좌측 폐문 (말초 기관의 접합과 대동맥의 아치와 왼쪽 폐동맥 사이의 왼쪽 주에서) 좌측 상엽의 교차점과 좌하 엽 기관지). </li><li> 실시간 초음파 유도 하에서, 기관지 벽에 구멍을 대상 병변에 바늘을 배치합니다. 니들 내에서 탐침을 제거하고 시간에 환부 10 ㎖ (1 밀리그램 / 시스플라틴 mL)에 시스플라틴을 주입. 시트 내의 바늘을 철회. </li><li> 전반에 걸쳐 약물의 주입을 용이하게하기 위해 다른 위치에서 세션 당 네 개의 천공 각 병변을 치료. 펑크 당 시스플라틴 10 mg을 주입한다. </li><li> 세션 당 두 개의 병변을 치료. 이상의 병변 세션 당 처리되는 경우, 40 mg를 초과하지 세션 당 총 투여 량과 시스플라틴 20mg을 각각 주입 사이트. </li><li> 가공용에서 바늘을 제거범위의 NG 채널. </li><li> 말초기도에서 추가 약물을 흡입하고, 기관 지경을 제거합니다. </li><li> 환자가 병원 프로토콜에 따라 복구하고 같은 날에 그들을 배출 할 수 있습니다. </li><li> 4 주 총 일주일에 한 번 (2.7-2.13 단계)에 시스플라틴 주입을 반복 (일 1, 8, 15, 22). 참고 : 처리되면, 특정 병변이 이후의 만남에 ITC와 재치료 고려해서는 안됩니다. </li></ol> 3. 포스트 분사 <ol><li> 후속 흉부 컴퓨터 단층 촬영 (CT)이나 양전자 방출 단층 촬영 (PET / CT)에 의해 응답을 평가하는 8-12주 마지막 치료 세션 후 스캔. 치료의 사이트에서 재발과 종격동, 폐문의 재발, 또는 쇄골 포사과 지역 재발과 국소 재발을 정의합니다. </li></ol>

<ol>
	<li>. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> International Agency for Research on Cancer. , (2012).</li><li>Siegel, R., Ma, J., Zou, Z., Jemal, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cancer+statistics,+2014.">Cancer statistics, 2014.</a> CA Cancer J Clin. 64 (1), 9-29 (2014).</li><li>Jeremic, B., Videtic, G. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Chest+reirradiation+with+external+beam+radiotherapy+for+locally+recurrent+non-small-cell+lung+cancer:+a+review.">Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review.</a> Int J Radiat Oncol Biol Phys. 80 (4), 969-977 (2011).</li><li>Perez, C. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Impact+of+irradiation+technique+and+tumor+extent+in+tumor+control+and+survival+of+patients+with+unresectable+non-oat+cell+carcinoma+of+the+lung:+report+by+the+Radiation+Therapy+Oncology+Group.">Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group.</a> Cancer. 50 (6), 1091-1099 (1982).</li><li>Hainsworth, J. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Weekly+docetaxel+with+either+gemcitabine+or+vinorelbine+as+second-line+treatment+in+patients+with+advanced+nonsmall+cell+lung+carcinoma:+Phase+II+trials+of+the+Minnie+Pearl+Cancer+Research+Network.">Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.</a> Cancer. 92 (9), 2391-2398 (2001).</li><li>Grossi, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phase+II+study+of+irinotecan+and+docetaxel+in+patients+with+previously+treated+non-small+cell+lung+cancer:+an+Alpe-Adria+Thoracic+Oncology+Multidisciplinary+group+study+(ATOM+007).">Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).</a> Lung Cancer. 52 (1), 89-92 (2006).</li><li>Celikoglu, F., Celikoglu, S. I. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoural+chemotherapy+with+5-fluorouracil+for+palliation+of+bronchial+cancer+in+patients+with+severe+airway+obstruction.">Intratumoural chemotherapy with 5-fluorouracil for palliation of bronchial cancer in patients with severe airway obstruction.</a> J Pharm Pharmacol. 55 (10), 1441-1448 (2003).</li><li>Eisenhauer, E. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=New+response+evaluation+criteria+in+solid+tumours:+revised+RECIST+guideline+(version+1.1).">New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</a> Eur J Cancer. 45 (2), 228-247 (2009).</li><li>Celikoglu, F., Celikoglu, S. I., York, A. M., Goldberg, E. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoral+administration+of+cisplatin+through+a+bronchoscope+followed+by+irradiation+for+treatment+of+inoperable+non-small+cell+obstructive+lung+cancer.">Intratumoral administration of cisplatin through a bronchoscope followed by irradiation for treatment of inoperable non-small cell obstructive lung cancer.</a> Lung Cancer. 51 (2), 225-236 (2006).</li><li>Celikoglu, S. I., Celikoglu, F., Goldberg, E. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Endobronchial+intratumoral+chemotherapy+(EITC)+followed+by+surgery+in+early+non-small+cell+lung+cancer+with+polypoid+growth+causing+erroneous+impression+of+advanced+disease.">Endobronchial intratumoral chemotherapy (EITC) followed by surgery in early non-small cell lung cancer with polypoid growth causing erroneous impression of advanced disease.</a> Lung Cancer. 54 (3), 339-346 (2006).</li><li>Kilburn, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Management+of+mediastinal+relapse+after+treatment+with+stereotactic+body+radiotherapy+or+accelerated+hypofractionated+radiotherapy+for+stage+I/II+non-small-cell+lung+cancer.">Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.</a> J Thorac Oncol. 9 (4), 572-576 (2014).</li><li>Goldberg, E. P., Hadba, A. R., Almond, B. A., Marotta, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoral+cancer+chemotherapy+and+immunotherapy:+opportunities+for+nonsystemic+preoperative+drug+delivery.">Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery.</a> J Pharm Pharmacol. 54 (2), 159-180 (2002).</li><li>Sandler, A. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phase+III+trial+of+gemcitabine+plus+cisplatin+versus+cisplatin+alone+in+patients+with+locally+advanced+or+metastatic+non-small-cell+lung+cancer.">Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.</a> J Clin Oncol. 18 (1), 122-130 (2000).</li><li>Ciotti, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prospective+evaluation+of+anthracycline-related+early+cardiac+damage:+how+do+we+monitor+it.">Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it.</a> J Clin Oncol. 19 (22), 4269-4270 (2001).</li><li>Burris, H. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoral+cisplatin/epinephrine-injectable+gel+as+a+palliative+treatment+for+accessible+solid+tumors:+a+multicenter+pilot+study.">Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study.</a> Otolaryngol Head Neck Surg. 118 (4), 496-503 (1998).</li><li>Vogl, T. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CT-guided+intratumoural+administration+of+cisplatin/epinephrine+gel+for+treatment+of+malignant+liver+tumours.">CT-guided intratumoural administration of cisplatin/epinephrine gel for treatment of malignant liver tumours.</a> Br J Cancer. 86 (4), 524-529 (2002).</li><li>Monga, S. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Endoscopic+treatment+of+gastric+cancer+with+intratumoral+cisplatin/epinephrine+injectable+gel:+a+case+report.">Endoscopic treatment of gastric cancer with intratumoral cisplatin/epinephrine injectable gel: a case report.</a> Gastrointest Endosc. 48 (4), 415-417 (1998).</li><li>Monga, S. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intratumoral+therapy+of+cisplatin/epinephrine+injectable+gel+for+palliation+in+patients+with+obstructive+esophageal+cancer.">Intratumoral therapy of cisplatin/epinephrine injectable gel for palliation in patients with obstructive esophageal cancer.</a> Am J Clin Oncol. 23 (4), 386-392 (2000).</li><li>Shepherd, F. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prospective+randomized+trial+of+docetaxel+versus+best+supportive+care+in+patients+with+non-small-cell+lung+cancer+previously+treated+with+platinum-based+chemotherapy.">Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.</a> J Clin Oncol. 18 (10), 2095-2103 (2000).</li><li>Hanna, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Randomized+phase+III+trial+of+pemetrexed+versus+docetaxel+in+patients+with+non-small-cell+lung+cancer+previously+treated+with+chemotherapy.">Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.</a> J Clin Oncol. 22 (9), 1589-1597 (2004).</li></ol>

The authors have nothing to disclose.

<html> 우리의 원고는 더 많은 방사선이 옵션을 선택하지 않습니다 누구에 환자의 폐암의 고립 된 종격동 및 폐문 재발의 관리에 초점을 맞추고있다. IMHR의 발생 빈도는 약 9 % (11)이다. 다른 치료 방법은 고식적 항암 화학 요법, 더 많은 외부 빔 방사선 치료, 또는지지 요법 및 감시를 포함하여, 이러한 환자에서 시도되고있다. 우리 기관에서, 우리는 기관지 내시경에 의해 유도 종양...

폐암은 모든 암 관련 사망의 5 일에 대한 남성과 여성 모두와 계정에서 전 세계적으로 가장 널리 퍼진 암이다. 그것은 0.87 1, 2의 경우 치사율이 있습니다. 초기 치료 후 재발 폐암 환자에서 대부분의 사망자를 차지한다. 재발 성 폐암에 대한 치료 옵션이 제한됩니다. 재발 성 폐암은 더 개입 (3)에 수용과 관용의 가능성을 감소 모두의 삶의 질에 상당한 교사 단선에 상당한 손상에 이르게 추가지지 요법이 필요합니다. 비소 세포 폐암 환자의 약 30 %는 방사선 사 후 국소 재발이있다. 이들 환자에 대한 치료 옵션은 제한적이며 10 % (5), (6)의 대물 응답 속도가 전신 화학 요법을 포함한다.반복 흉부 방사선이 가능하지만, 그 목적 완화 및 증상 완화 주로 연구되었다 질병 관해 3에 사용되지 않았다. 우리 기관에서, 기관지 내시경을 통해 액세스 격리 된 종격동 및 폐문 재발 (IMHR) 모든 환자는 시스플라틴의 기관지 종양 내 주사 (ITC)를 -guided 기관지 초음파 (EBUS)로 처리 하였다. 전신 화학 요법 및 / 또는 외부 빔 방사선 요법 (EBRT)와 동시 치료는 치료 종양 &#39;재량권에 따라시켰다. 이 원고는 안전성, 유효성, 타당성, 그리고 우리의 기관에서 사용되는 프로토콜에 대한 자세한 방법을 강조한다.

<table><tbody><tr><td>Bronchoscope</td><td></td><td></td><td></td></tr><tr><td>22 Guage olympus EBUS needle</td><td></td><td></td><td></td></tr><tr><td>40 g of cisplatin in 40 mL of normal saline</td><td></td><td></td><td></td></tr></tbody></table>

endobronchial ultrasound-guided intratumoral injection of cisplatin for the treatment of isolated mediastinal recurrence of lung cancer

폐암 환자의 격리 된 폐문 및 외부 빔 방사선 요법 (EBRT) 다음 종격동 재발 (IMHR)이 일반적이다. 이 환자들은 많은 치료 옵션이없는 일반적으로 고식적 항암 화학 요법 또는 최선의지지 요법을 제공됩니다. 기관지 초음파 (EBUS)는 시스플라틴의 종양 내 주입을 -guided (ITC)는 이러한 환자에 대한 새로운 접근 방식이다. 절차는 수면 마취 하에서 수행된다. 병변은 EBUS를 사용하여 기관지에 위치되고, 22 게이지 바늘 EBUS 범위의 워킹 채널을 통해 전진 위치에 고정된다. 초음파 안내 하에서, 기관지 벽의 천공 바늘은 표적 병변에 이동된다. 니들 탐침이어서 제거되고 시스플라틴은 (40 밀리그램 / 40 mL)을 환부에 주입된다. 한 두 사이트는 세션 당 처리됩니다. 절차의 세부 사항은 용지의 프로토콜 섹션에 설명되어 있습니다. 우리 센터에서 50 사이트는 36 명에서 치료를 받았다(19 남성, 17 여성). 우리의 코호트의 평균 연령은 61.9 ± 8.5 세였다. 우리는 35 명, 41 사이트에 최종 분석을 수행 하였다. 35분의 11 (31 %)이 안정 또는 진행성 질환 (비 대응)을 가지고, 반면 35분의 24 (69 %)은 전체 또는 부분 반응 (대응)를 가지고 있었다. 전반적으로, 우리 그룹의 생존하지 않았다 것보다 훨씬 더 나은 생존을 갖는 반응했다 환자 8 개월 (6-11개월의 95 % CI)이었다.

응답은 8~12주 치료 후 후속 촬상하여 측정 하였다. 반응은 완전 관해 (CR), 부분 관해 (PR), 안정한 질환 (SD), 진행성 질환 (PD), 또는 8 RECIST 1.1 기준에 기초하여 응답을 평가할 수없는 것으로 분류 하였다. CR과 PR 환자는 조치로 간주하고, 나머지는 비 반응 군으로 분류 하였다. 이차 결과는 종양의 조직 학적, 재발의 크기, 동시 전신 요법에 따라 응답을 포함. ...

Watch this Scientific Journal Video about Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer at JoVE.com

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

The management of isolated recurrent lung cancer in a previously-irradiated field is challenging. Here, we describe an endobronchial ultrasound (EBUS)-guided cisplatin injection for the management of patients with localized lung cancer recurrence in a previously-radiated field.

기관지 폐암의 고립 된 종격동 재발의 치료에 시스플라틴의 종양 내 주입을 초음파 유도

Isolated hilar and mediastinal recurrence (IMHR) following external beam radiation therapy (EBRT) in patients with lung cancer is common. These patients ...

endobronchial-ultrasound-guided-intratumoral-injection-cisplatin-for

Universidad de Cartagena UDEC

Research

JoVE Journal

Cancer Research

10.4K 조회수.  University of Florida College of Medicine. The management of isolated recurrent lung cancer in a previously-irradiated field is challenging. Here, we describe an endobronchial ultrasound (EBUS)-guided cisplatin injection for the management of patients with localized lung cancer recurrence in a previously-radiated field. 

비디오: Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

The use of mouse models is indispensable for studying the pathophysiology of various diseases. With respect to lung cancer, several models are available, including genetically engineered models as well as transplantation models. However, genetically engineered mouse models are time-consuming and expensive, whereas some orthotopic transplantation models are difficult to reproduce. Here, a non-invasive intratracheal delivery method of lung tumor cells as an alternative orthotopic transplantation model is described. The use of mouse lung adenocarcinoma cells and syngeneic graft recipients allows studying tumorigenesis under the presence of a fully active immune system. Furthermore, genetic manipulations of tumor cells before transplantation makes this model an attractive time-saving approach to study the impact of genetic factors on tumor growth and tumor cell gene expression profiles under physiological conditions. Using this model, we show that lung adenocarcinoma cells express increased levels of the T-cell suppressor programmed death-ligand 1 (PD-L1) when grown in their natural environment as compared to cultivation in vitro.

Here we describe a minimally invasive syngeneic orthotopic transplantation model of mouse lung adenocarcinoma cells as a time- and cost-reducing model to study non-small cell lung cancer.

Orthotopic PD L1 식 공부 Syngeneic 폐 선 암 세포의 이식

The use of mouse models is indispensable for studying the pathophysiology of various diseases. With respect to lung cancer, several models are available, ...

연구

암 연구학

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Substernal thyroid goiter (STG) represents about 5.8% of all mediastinal lesions1. There is a wide variation in the published incidence rates due to the lack of a standardized definition for STG. Biopsy is often required to differentiate benign from malignant lesions. Unlike cervical thyroid, the overlying sternum precludes ultrasound-guided percutaneous fine needle aspiration of STG. Consequently, surgical mediastinoscopy is performed in the majority of cases, causing significant procedure related morbidity and cost to healthcare. Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is a frequently used procedure for diagnosis and staging of non-small cell lung cancer (NSCLC). Minimally invasive needle biopsy for lesions adjacent to the airways can be performed under real-time ultrasound guidance using EBUS. Its safety and efficacy is well established with over 90% sensitivity and specificity. The ability to perform EBUS as an outpatient procedure with same-day discharges offers distinct morbidity and financial advantages over surgery. As physicians performing EBUS gained procedural expertise, they have attempted to diversify its role in the diagnosis of non-lymph node thoracic pathologies. We propose here a role for EBUS-TBNA in the diagnosis of substernal thyroid lesions, along with a step-by-step protocol for the procedure.

Substernal thyroid lesions are common, and need to be differentiated from malignancy. Obtaining percutaneous fine needle biopsy is not possible due to its retrosternal location. This article proposes a protocol for biopsy of substernal thyroid lesions using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA).

흉골 하 갑상선 조직 검사는 기관지 초음파 유도 기관지 바늘 흡인을 사용하여

Substernal thyroid goiter (STG) represents about 5.8% of all mediastinal lesions1. There is a wide variation in the published incidence rates due to the ...

의학

Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System

Respiratory disease studies typically involve the use of murine models as surrogate systems. However, there are significant physiologic differences between the murine and human respiratory systems, especially in their upper respiratory tracts (URT). In some models, these differences in the murine nasal cavity can have a significant impact on disease progression and presentation in the lower respiratory tract (LRT) when using intranasal instillation techniques, potentially limiting the usefulness of the mouse model to study these diseases. For these reasons, it would be advantageous to develop a technique to instill bacteria directly into the mouse lungs in order to study LRT disease in the absence of involvement of the URT. We have termed this lung specific delivery technique intubation-mediated intratracheal (IMIT) instillation. This noninvasive technique minimizes the potential for instillation into the bloodstream, which can occur during more invasive traditional surgical intratracheal infection approaches, and limits the possibility of incidental digestive tract delivery. IMIT is a two-step process in which mice are first intubated, with an intermediate step to ensure correct catheter placement into the trachea, followed by insertion of a blunt needle into the catheter to mediate direct delivery of bacteria into the lung. This approach facilitates a &#62;98% efficacy of delivery into the lungs with excellent distribution of reagent throughout the lung. Thus, IMIT represents a novel approach to study LRT disease and therapeutic delivery directly into the lung, improving upon the ability to use mice as surrogates to study human respiratory disease. Furthermore, the accuracy and reproducibility of this delivery system also makes it amenable to Good Laboratory Practice Standards (GLPS), as well as delivery of a wide range of reagents which require high efficiency delivery to the lung.

Intubation-mediated Intratracheal IMIT Instillation: A Noninvasive, Lung-specific Delivery System

Intubation-mediated intratracheal (IMIT) instillation of reagents is an excellent, noninvasive method for studying respiratory disease, as well as a method for instilling therapeutic reagents directly into the lung. It is a rapid and highly reproducible method which is suitable for preclinical testing.

삽관 매개 기관 내 (IMIT) 떨어 뜨림 : 비 침습적, 폐 별 전달 시스템

Respiratory disease studies typically involve the use of murine models as surrogate systems. However, there are significant physiologic differences ...

Orthotopic NSCLC를 모델링하기 위한 다세포 스페로이드의 폐내 접종

Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities

Non-small cell lung cancer (NSCLC) is a highly lethal disease with a complex and heterogeneous tumor microenvironment. Currently, common animal models based on subcutaneous inoculation of cancer cell suspensions do not recapitulate the tumor microenvironment in NSCLC. Herein we describe a murine orthotopic lung cancer xenograft model that employs the intrapulmonary inoculation of three-dimensional multicellular spheroids (MCS). Specifically, fluorescent human NSCLC cells (A549-iRFP) were cultured in low-attachment 96-well microplates with collagen for 3 weeks to form MCS, which were then inoculated intercostally into the left lung of athymic nude mice to establish the orthotopic lung cancer model.
Compared with the original A549 cell line, MCS of the A549-iRFP cell line responded similarly to anticancer drugs. The long-wavelength fluorescent signal of the A549-iRFP cells correlated strongly with common markers of cancer cell growth, including spheroid volume, cell viability, and cellular protein level, thus allowing dynamic monitoring of the cancer growth in vivo by fluorescent imaging. After inoculation into mice, the A549-iRFP MCS xenograft reliably progressed through phases closely resembling the clinical stages of NSCLC, including the expansion of the primary tumor, the emergence of neighboring secondary tumors, and the metastases of cancer cells to the contralateral right lung and remote organs. Moreover, the model responded to the benchmark antilung cancer drug, cisplatin with the anticipated toxicity and slower cancer progression. Therefore, this murine orthotopic xenograft model of NSCLC would serve as a platform to recapitulate the disease&#39;s progression and facilitate the development of potential anticancer drugs.

저자 스포트라이트: 항암제의 나노제형 개발을 위한 쥐 비소세포폐암 모델 확립

This study presents an orthotopic non-small cell lung cancer (NSCLC) model based on intrapulmonary inoculation of multicellular spheroids of fluorescent A549-iRFP cells. The model recapitulates clinical NSCLC stages and responds to cisplatin, according to dynamic in vivo monitoring of long-wavelength fluorescence.

비소세포폐암의 기형외형 이종이식 모델 구축: 질병 진행 모방 및 약물 활성성 예측

Non-small cell lung cancer (NSCLC) is a highly lethal disease with a complex and heterogeneous tumor microenvironment. Currently, common animal models ...

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Physicians considering stereotactic ablative body radiation therapy (SBRT) for the treatment of extracranial cancer targets must be aware of the sizeable risks for normal tissue injury and the hazards of physical tumor miss. A first-of-its-kind SBRT platform achieves high-precision ablative radiation treatment through a combination of versatile real-time imaging solutions and sophisticated tumor tracking capabilities. It uses dual-diagnostic kV x-ray units for stereoscopic open-loop feedback of cancer target intrafraction movement occurring as a consequence of respiratory motions and heartbeat. Image-guided feedback drives a gimbaled radiation accelerator (maximum 15 x 15 cm field size) capable of real-time &#177;4 cm pan-and-tilt action. Robot-driven &#177;60&#176; pivots of an integrated &#177;185&#176; rotational gantry allow for coplanar and non-coplanar accelerator beam set-up angles, ultimately permitting unique treatment degrees of freedom. State-of-the-art software aids real-time six dimensional positioning, ensuring irradiation of cancer targets with sub-millimeter accuracy (0.4 mm at isocenter). Use of these features enables treating physicians to steer radiation dose to cancer tumor targets while simultaneously reducing radiation dose to normal tissues. By adding respiration correlated computed tomography (CT) and 2-[18F] fluoro-2-deoxy-&#7429;-glucose (18F-FDG) positron emission tomography (PET) images into the planning system for enhanced tumor target contouring, the likelihood of physical tumor miss becomes substantially less1. In this article, we describe new radiation plans for the treatment of moving lung tumors.

Stereotactic ablative body radiation therapy (SBRT) involves the precise delivery of high-dose radiation to cancer tumor targets. A novel SBRT platform offers a first-of-its-kind gimbaled radiation accelerator mounted within a pivoting O-ring gantry capable of dynamic image-guided tumor tracking. Here, we describe dynamic tumor tracking for lung targets.

정위 절제 바디 방사선 치료에 대한 동적 폐 종양 추적

Physicians considering stereotactic ablative body radiation therapy (SBRT) for the treatment of extracranial cancer targets must be aware of the sizeable ...

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

The prognosis of patients with metastatic cancers has improved in the past decades due to effective chemotherapy and oligometastatic surgery. For inoperable patients, local ablation therapies, such as stereotactic body radiotherapy (SBRT), can provide effective local tumor control with minimal toxicity. Because of its high precision and accuracy, SBRT delivers a higher radiation dose per fraction, is more effective, and targets smaller irradiation volumes than does conventional radiotherapy. In addition, steep dose gradients from target lesions to surrounding normal tissues are achieved using SBRT; thus, SBRT provides more effective tumor control and exhibits fewer side effects than conventional radiotherapy. The use of SBRT is prevalent for treating intracranial lesions (known as stereotactic radiosurgery); however, it is now also used for treating spinal and adrenal metastases. Because of advancements in image-guided assistance and respiratory motion management, several studies have investigated the use of SBRT for treating lung or liver tumors, which move as a patient breathes. The results of these studies have suggested that SBRT favorably controls tumors in the case of moving lesions.
Four-dimensional computed tomography (4D-CT) with an abdominal compressor (AC) is clinically convenient for effective respiratory motion management. Because this method is noninvasive and allows free breathing, its use reduces complications. Furthermore, patients consider this method convenient. Moreover, it is considered more efficient than other methods of respiratory motion management by physicians and therapists. The use of 4D-CT with an AC for treating pulmonary lesions has also been widely investigated, and the technique is gaining acceptance for treating hepatic lesions. However, the protocols for using 4D-CT with an AC for treating hepatic lesions are different from those used for treating pulmonary lesions. In this article, we describe a new protocol for SBRT with 4D-CT and an AC for treating liver metastases.

Stereotactic body radiotherapy (SBRT) requires rigorous accuracy and precision for delivering high radiation doses per fraction to small treatment volumes to improve tumor control and simultaneously reduce toxicity. Herein, we present a noninvasive and clinically convenient respiratory motion management protocol for SBRT for liver metastases.

몸 정위 적 방사선 치료에 대 한 내부 대상 볼륨 메서드를 사용 하 여 간 전이의 치료

The prognosis of patients with metastatic cancers has improved in the past decades due to effective chemotherapy and oligometastatic surgery. For ...

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Intratracheal (IT) administration of experimental agents is an essential technique in murine models of diffuse lung diseases, such as bleomycin-induced pulmonary fibrosis.&#160; However, distribution of intratracheally-administered agents to the distal mouse lung is often asymmetric, with lung parenchymal concentrations increased in the smaller (but equally accessible) left lung of the mouse.&#160; Described in this report is a novel intrabronchial (IB) approach to cannulate the left and/or right lungs of living mice non-operatively.&#160; It is also demonstrated how this approach can be used to selectively administer agents to one lung or adapted (via dose-adjusted IB delivery) to improve the left-right symmetry of lung delivery of experimental agents, thereby improving models of diffuse lung disease such as bleomycin-induced pulmonary fibrosis.

Intratracheal (IT) administration of experimental agents in mice often results in asymmetric delivery to the distal lungs.&#160; In this report, we describe a direct intrabronchial (IB) approach to cannulate each lung in living mice non-operatively.&#160; This approach can be used to selectively administer agents to one lung or may be adapted to improve the symmetric agent delivery to both lungs.

마우스 폐 내 선택적 에이전트 침착을 개선하기 위한 직접 기관내 투여

Intratracheal (IT) administration of experimental agents is an essential technique in murine models of diffuse lung diseases, such as bleomycin-induced ...

A Stepwise Approach for Performing Ultrasound Guided Transthoracic Lung Biopsy

Diagnosing patients with radiological lung lesions, especially those suspected of having primary lung cancer, is a common and critical clinical scenario. When selecting the most suitable invasive procedure to establish a diagnosis in these cases, a delicate balance must be struck between achieving a high diagnostic yield, providing staging information, minimizing potential complications, enhancing the patient experience, and controlling costs. The integration of thoracic ultrasound as a routine clinical tool in respiratory medicine has led to increased awareness and utilization of ultrasound-guided invasive techniques in chest procedures, including transthoracic biopsies. By following a systematic and stepwise approach, transthoracic ultrasound-guided lung biopsy emerges as a safe, cost-effective procedure with a remarkable diagnostic accuracy. These attributes collectively position it as an ideal invasive technique when technically feasible. Consequently, in patients presenting subpleural lung lesions suspected of malignancy, transthoracic ultrasound-guided lung biopsy has become a standard procedure in the realm of modern invasive pulmonology.

Transthoracic ultrasound-guided lung biopsy represents a safe, cost-effective, and efficient approach for patients presenting with subpleural lung lesions suspected of malignancy. Employing a systematic, step-by-step process is crucial to achieve optimal patient selection, minimize complication risks, and maximize diagnostic accuracy.

Diagnosing patients with radiological lung lesions, especially those suspected of having primary lung cancer, is a common and critical clinical scenario. ...

기관지 폐암의 고립 된 종격동 재발의 치료에 시스플라틴의 종양 내 주입을 초음파 유도

요약

더 많은 비디오 탐색

이 비디오의 챕터

Orthotopic PD L1 식 공부 Syngeneic 폐 선 암 세포의 이식

흉골 하 갑상선 조직 검사는 기관지 초음파 유도 기관지 바늘 흡인을 사용하여

삽관 매개 기관 내 (IMIT) 떨어 뜨림 : 비 침습적, 폐 별 전달 시스템

비소세포폐암의 기형외형 이종이식 모델 구축: 질병 진행 모방 및 약물 활성성 예측

비소세포폐암의 기형외형 이종이식 모델 구축: 질병 진행 모방 및 약물 활성성 예측

비소세포폐암의 기형외형 이종이식 모델 구축: 질병 진행 모방 및 약물 활성성 예측

정위 절제 바디 방사선 치료에 대한 동적 폐 종양 추적

몸 정위 적 방사선 치료에 대 한 내부 대상 볼륨 메서드를 사용 하 여 간 전이의 치료

마우스 폐 내 선택적 에이전트 침착을 개선하기 위한 직접 기관내 투여

A Stepwise Approach for Performing Ultrasound Guided Transthoracic Lung Biopsy